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Original Article
Phosphatidylinositol 3-Kinase Pathway Genomic Alterations 
in 60,991 Diverse Solid Tumors Informs Targeted Therapy 
Opportunities
Sherri Z. Millis, PhD1; Denis L. Jardim, MD, PhD2; Lee Albacker, PhD1; Jeffrey S. Ross, MD1; Vincent A. Miller, MD1;  
Siraj M. Ali, MD, PhD1; and Razelle Kurzrock, MD 3
BACKGROUND: The phosphatidylinositol 3-kinase (PI3K) pathway is frequently altered in cancer. This report describes the  landscape 
of PI3K alterations in solid tumors as well as co-alterations serving as potential resistance/attenuation mechanisms. METHODS: 
Consecutive samples were analyzed in a commercial Clinical Laboratory Improvement Amendment-certified laboratory using 
 comprehensive genomic profiling performed by next-generation sequencing (315 genes). The co-alterations evaluated included the 
Erb-B2 receptor tyrosine kinase 2 (ERBB2), ERBB3, ERBB4, RAS, MET proto-oncogene tyrosine kinase (MET), and mitogen- activated 
protein kinase kinase (MAP2K) genes as well as tumor protein 53 (TP53), estrogen receptor 1 (ESR1), and androgen receptor (AR). 
RESULTS: Alterations in any of 18 PI3K-pathway associated genes were identified in 44% of 60,991 tumors. Although single base and 
insertions/deletions (indels) were the most frequent alterations, copy number changes and rearrangements were identified in 11% 
and 0.9% of patients, respectively. Overall, the most frequently altered genes were PIK3 catalytic subunit α (PIK3CA) (13%), 
 phosphatase and tensin homolog (PTEN) (9%), and serine/threonine kinase 11 (STK11) (5%). Tumor types that frequently harbored at 
least 1 PI3K alteration were uterine (77%), cervical (62%), anal (59%), and breast (58%) cancers. Alterations also were discerned fre-
quently in tumors with carcinosarcoma (89%) and squamous cell carcinoma (62%) histologies. Tumors with a greater likelihood of 
co-occurring PI3K pathway and MAPK pathway alterations included colorectal cancers (odds ratio [OR], 1.64; P < .001),  mesotheliomas 
(OR, 2.67; P = .024), anal cancers (OR, 1.98; P = .03), and nonsquamous head and neck cancers (OR, 2.03; P = .019). The  co-occurrence 
of ESR1 and/or AR alterations with PI3K alterations was statistically significant in bladder, colorectal, uterine, prostate, and unknown 
primary cancers. CONCLUSIONS: Comprehensive genomic profiling reveals altered PI3K-related genes in 44% of solid malignancies, 
including rare disease and histology types. The frequency of alterations and the co-occurrence of resistance pathways vary by tumor 
type, directly affecting opportunities for targeted therapy. Cancer 2019;125:1185-1199. © 2018 The Authors. Cancer published by 
Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons 
Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is 
properly cited and is not used for commercial purposes. 
KEYWORDS: cancer genome, molecular profile, phosphoinositide 3-kinase catalytic subunit α (PIK3CA), precision oncology, 
targeted therapy.
INTRODUCTION
The phosphatidylinositol 3-kinase (PI3K) pathway is frequently deregulated in human cancers, and the catalytic PI3K 
subunit P110 is the mediator of the effects of many deregulated extracellular tyrosine kinase receptors. Moreover, other 
major nodes of this pathway, including AKT serine/threonine kinase (AKT) and mammalian target of rapamycin 
(mTOR), can be activated though constitutive or redundant intracellular processes.1 Negative regulators of the PI3K 
pathway, such as phosphatase and tensin homolog (PTEN), also have been well characterized. This important cancer 
pathway is involved in important fluctuating processes that promote malignant growth and resistance.2,3
Altered PI3K signaling may be caused by several types of genomic alterations, including mutation, amplification, 
and methylation.4 Indeed, across various solid tumor types sampled from patients with cancer in a hot-spot analysis 
of known regions of PI3K pathway genes, at least 1 PI3K pathway alteration was described in 38%.5 Malignancies 
frequently associated with PI3K alterations include endometrial, breast, lung, and prostate cancers,6-8 but almost any 
tumor type can harbor PI3K genomic alterations in a subset of patients.5 Because of the importance of this pathway for 
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human cancers, numerous small molecules targeted to 
inhibit different steps of its activation have entered clini-
cal development.4,6
However, despite extensive drug-development 
 efforts over many years, few PI3K pathway inhibitors 
actually have been approved. Approvals were obtained 
for everolimus, temsirolimus (both of which are mTOR 
inhibitors), and idelalisib (which blocks the p110-δ sub-
unit of the PI3K enzyme). Recently, copanlisib, a potent 
PI3K-α and PI3K-δ inhibitor (but with significant inhib-
itory activity against PI3K-β and PI3K-γ) was approved 
for lymphomas.9 However, many other drugs failed to 
demonstrate clinical efficacy.10,11 Overall, PI3K inhibi-
tors are characterized by low activity as monotherapies, 
an absence of well characterized genomic predictive 
markers, and redundant mechanisms of resistance.12,13
Recently, targeted therapies developed under a bio-
marker-driven rationale have exhibited greater efficacy 
and a more successful development pathway compared 
with agents that were developed for unselected patients 
with cancer.14-17 However, biomarker-driven studies are 
not always successful.18 The reasons why this type of 
development has been less successful for PI3K-directed 
agents are not clear but could be related to the mole-
cules themselves or to co-existing resistance pathways. 
Indeed, it is well known that mitogen-activated protein 
kinase kinase (MEK) pathway alterations are more com-
mon in patients with PI3K signaling anomalies than in 
those without such anomalies and that MEK anomalies 
can mediate resistance.19,20 An in-depth characterization 
of the PI3K genomic landscape, along with a descrip-
tion of concomitant genetic alterations that could lead 
to resistance to pathway inhibition, is urgently needed. 
Herein, we characterize the PI3K-related genomic port-
folios of 60,991 patients, including rare disease and his-
tology types not previously well assessed, who underwent 
clinical-grade next-generation sequencing.
MATERIALS AND METHODS
Tissue Sampling
Consecutive samples submitted by thousands of 
 physicians world-wide were analyzed using a  commercial 
Clinical Laboratory Improvement Amendment-
certified laboratory (Foundation Medicine, Inc, 
Cambridge, MA; available at: https://www.founda-
tionmedicine.com). Indications for genomic testing 
were at the discretion of the ordering physicians. Tissue 
diagnoses were designated according to the pathology 
report described by the ordering physicians and further 
verified by a pathologist at Foundation Medicine. DNA 
was extracted from formalin-fixed, paraffin-embedded 
tissue, as previously described.21 Patient identifica-
tion was anonymized for the study. Approval for the 
Foundation Medicine cohort, including a waiver of 
 informed consent and a Health Insurance Portability 
and Accountability Act of 1996 waiver of authoriza-
tion, was obtained from the Western Institutional 
Review Board (protocol no. 20152817).
Next-Generation Sequencing
DNA was extracted from formalin-fixed, paraffin- 
embedded sections, and comprehensive genomic profil-
ing was performed on hybridization-captured, adaptor 
ligation-based libraries to a median depth of coverage 
of >500X.21 The platform simultaneously sequenced the 
coding regions of 315 cancer-related genes plus introns 
from 28 genes that often are rearranged or altered in 
cancer. Alterations captured by next-generation sequenc-
ing included base-pair substitutions, insertions/deletions 
(both short and long), copy-number alterations, and 
rearrangements.
Clustering of Genetic Alterations and 
Tumor Types
Genomic alterations were classified as activators of the 
PI3K pathway (18 genes) or mediators of PI3K resistance 
(Supporting Table 1). An analysis of frequencies was per-
formed according to disease ontologies (clustered accord-
ing to the American Joint Committee on Cancer’s AJCC 
Cancer Staging Handbook, seventh edition)22 and also ac-
cording to tumor histologies (according to the ordering 
physician’s pathology report).
Statistical Analysis
Statistical analysis was performed using GraphPad 
Prism (GraphPad Software, La Jolla, CA), Python 2.7 
(Python Software Foundation, Beaverton, OR), and 
Anaconda (version 4-4.3.21; Anaconda Inc, Austin, 
TX). A  co-occurrence analysis was performing matching 
genomic alterations in the PI3K pathway with 3 differ-
ent subsets of genomic alterations (the mitogen-activated 
kinase [MAPK] pathway, the tumor protein 53 [TP53] 
pathway, and the estrogen receptor 1 [ESR1] and/or 
 androgen receptor [AR] [hormone receptor] pathway).
RESULTS
Alterations in any gene of the PI3K pathway were iden-
tified in 44% of the 60,991 tumors analyzed (Fig. 1). 
The most frequently altered gene was PIK3 catalytic 
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subunit α (PIK3CA) (13.3%), followed by PTEN (9.4%), 
serine/threonine kinase 11 (STK11) (4.8%), and F-box 
and WD repeat domain containing 7 (FBXW7) (3.4%) 
(Fig. 1C,F). Alterations in some genes were rare in our 
population, including regulatory-associated protein of 
mTOR/independent companion of mTOR complex 2 
(RICTOR) (0.02%), PIK3 regulatory subunit 2 (PIK3R2) 
(0.36%), and inositol polyphosphatate-4-phosphatase 
type IIB (INPP4B) (0.43%). Important variations in the 
frequency of PI3K alterations were detected according to 
histology and tumor type.
Analysis by Histology
The distribution of alterations of 18 genes in the PI3K 
pathway was analyzed according to histology. Sixteen 
histologies were evaluated, and all had at least 1 PI3K 
pathway alteration (Fig. 1A-C). There was significant 
variation in the patterns of PI3K alterations between 
histologies. Carcinosarcomas (89% had PI3K pathway 
alterations) and squamous cell carcinomas (62% had PI3K 
pathway alterations) were the most altered histologies, 
whereas sarcomas (16% had PI3K pathway alterations), 
mesotheliomas (14% had PI3K pathway alterations), and 
gastrointestinal stromal tumors (GISTs) (11% had PI3K 
pathway alterations) were the least common.
PIK3CA was the most frequently altered gene across 
the 16 histologies (13% overall) and was altered in every 
histology evaluated (Fig. 1B). Carcinosarcomas had the 
highest incidence of PIK3CA alteration (28% had PIK3CA 
alterations), followed by squamous cell carcinomas (23% 
had PIK3CA alterations), urothelial carcinomas (19% had 
PIK3CA alterations), adenocarcinomas (15% had PIK3CA 
alterations), and adenosquamous carcinomas (14% had 
PIK3CA alterations). Although PIK3CA was altered most 
frequently across histologies, at a 1.4 times higher rate 
than PTEN (13% vs 9% had PIK3CA alterations), a sub-
set of histologies had significantly higher rates (P < .0001) 
of PTEN alterations than PIK3CA alterations: these 
 included gliomas (29% vs 12%), melanomas (12% vs 3%), 
neuroendocrine tumors (10% vs 5%), and GISTs (5% vs 
0%). Although the difference was not significant, PTEN 
also was altered at a higher rate than PIK3CA in undiffer-
entiated carcinomas (21% vs 11%; P = .0755).
Other alteration rates to note by histology included 
RICTOR, which was altered at a very low rate overall 
(0.02% of patients) but was altered in all histologies ex-
cept adenoid cystic. Urothelial cancers had a significantly 
higher rate of tuberous sclerosis complex subunit 1 (TSC1) 
alterations than all other histologies (8% vs 0%-2%), 
whereas carcinosarcomas had a significantly higher rate of Fi
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AKT serine/threonine kinase 2 (AKT2) alterations than 
other histologies (12% vs 1%-3%). STK11 was altered 
at a 5% rate across histologies but was aberrant in 14% 
and 16% of patients with adenosquamous and large-cell 
carcinomas, respectively. Although PIK3R2 and regula-
tory-associated protein of mTOR complex 1 (RPTOR) 
were altered at a slightly higher rate than RICTOR (0.36% 
and 0.44%, respectively), they were the least frequently 
altered genes according to histology and were altered in 
11 of the 16 histologies at a rate of 1% or less.
Analysis by Disease Type
Six of the 34 disease types had higher rates of PI3K 
pathway alterations than the overall average of 44%, 
 including 4 of 5 “female” cancers (ie, cancers of the 
uterus [77% of patients had an alteration], cervix [62%], 
breast [58%], and vagina/vulva [46%]) (Fig. 1D-F). The 
exception was ovarian cancers, which were altered in 
30% of patients. Lung cancers, including large cell car-
cinomas and nonsmall cell lung cancers (NSCLCs), had 
alterations in 39% and 38% of patients, respectively; 
whereas small cell lung cancers were altered in 30% of 
patients. Soft tissue sarcomas and adrenal gland cancers 
were the least frequently altered (in 11% of patients), 
whereas testis cancers had the lowest number of altered 
PI3K pathway genes (only 6 of 18 genes) (Fig. 1E).
PIK3CA was altered most frequently across disease 
types (13% of patients had an alteration) and was the 
only gene altered in every disease type. PTEN was altered 
in 9% of patients and in all but 1 disease type (adrenal 
gland). Notably, in addition to the female cancers listed 
above, anus cancer also had a higher than  average num-
ber of alterations in both PIK3CA and PTEN. Similar 
to histologic differences, several cancers had signifi-
cantly higher rates (P < .0001) of PTEN alterations than 
PIK3CA alterations, including melanoma (12%), brain 
cancer (25%), prostate cancer (34%), and bone can-
cer (10%; P = .03). STK11 was altered at a significantly 
higher rate in cervical cancer, lung large cell carcinoma, 
and NSCLC, whereas altered FBXW7 was notably more 
frequent in corpus uteri cancer, anal cancer, colorectal 
cancer, and melanoma. TSC2 was altered in 5% of liver 
cancers, compared with 1% overall. Bladder (7%) and 
kidney (4%) cancers had significant more mutations in 
TSC1 compared with other disease types (1%).
Uterine cancers
Because uterine cancers had the highest overall rate of 
PI3K pathway alterations (77% of patients with uter-
ine cancer had alterations vs 62% of those with cervical 
cancer; P < .0001) and had a significantly higher per-
centage of PIK3R1 alterations than the next highest dis-
ease type (20%; P < .0001), we performed an additional, 
detailed analysis of the top PI3K pathway genes that 
were altered in this disease (see Fig. 1E,F). PIK3CA was 
 altered in 40% of patients, followed closely by PTEN. In 
2% of patients, PIK3R1 was the only PI3K gene  altered, 
whereas PIK3CA was the only PI3K gene altered in 10% 
of the uterine cancer cohort (with an overall uterine 
 cohort alteration rate of 40%).
Rare cancers
Rare cancers for which, to our knowledge, comprehensive 
genomic profiles have not been previously published by 
The Cancer Genome Atlas (TCGA) (although some have 
been reported outside of TCGA),23-26 include adenoid 
cystic, anus, neuroendocrine, nonmelanoma skin, sali-
vary gland, small intestine, thyroid, vaginal and vulvar, 
and unknown primaries (Fig. 2A-I). Unknown primaries 
differ in their genomic alterations, as might be suspected, 
based on the histologic differences described above. 
Thyroid cancers are primarily altered in PIK3CA and 
PTEN, including a higher proportion of PIK3CA altera-
tions in the anaplastic subtype (12%) compared with well 
differentiated thyroid cancers (5%). Higher proportions 
of genomic alterations in FBXW7, MTOR, PIK3CA, and 
STK11 were detected in vulvar cancers compared with 
vaginal cancers. Adenoid cystic cancers had very few 
 alterations in the PI3K pathway, but PIK3R1 alterations 
(6%) were detected more frequently compared with other 
cancers in general (2%). In anal cancers, higher frequen-
cies of alterations were detected in FBXW7, PIK3CA, 
and PTEN, which were observed almost exclusively in 
tumors that had squamous histology compared with 
basaloid carcinomas. Neuroendocrine cancers had low 
rates of PIK3CA alterations compared with other can-
cers (<10%). It is important to note the high frequency 
of PTEN alterations in prostate small cell carcinomas 
(35%), similar to prostate cancers overall (34%).
Co-Occurrence of PI3K Alterations and 
MAPK, TP53, and Hormone Receptor Pathway 
Alterations
The likelihood of a co-occurrence of an alteration in 
the PI3K pathway, in either the MAPK pathway or the 
hormone receptor pathway, or in TP53 was analyzed by 
disease type. Some tumors revealed a higher likelihood 
of a co-occurrence of alterations in both pathways com-
pared with an isolated alteration, especially for colorectal 
cancers (odds ratio [OR], 1.64; P < .001), mesotheliomas 
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Figure 2. Phosphoinositide 3-kinase (PI3K) pathway alterations are illustrated in rare or uncommon cancer types. The percentages 
of patients who had alterations are indicated. Numbers in parentheses represent the numbers of patients. The cancer types 
illustrated include: (A) unknown primaries, (B) thyroid, (C) adenoid cystic, (D) salivary gland, (E) skin (nonmelanoma), (F) vaginal 
and vulvar, (G) anus, (H) neuroendocrine tumors, and (I) small intestine. AKT1 indicates AKT serine/threonine kinase 1; AKT2, AKT 
serine/threonine kinase 2; AKT3, AKT serine/threonine kinase 3; FBXW7, F-box and WD repeat domain containing 7; INPP4B, 
inositol polyphosphatate-4-phosphatase type IIB; MTOR, mammalian target of rapamycin; NOS, not otherwise specified; PIK3C2B, 
PIK3 catalytic subunit 2β; PIK3CA, PIK3 catalytic subunit α; PIK3CB, PIK3 catalytic subunit β; PIK3CG, PIK3 catalytic subunit γ; 
PIK3R1, PIK3 regulatory subunit 1; PIK3R2, PIK3 regulatory subunit 2; PTEN, phosphatase and tensin homolog; RICTOR, regulatory-
associated protein of mTOR/independent companion of mTOR complex 2; RPTOR, regulatory-associated protein of mTOR complex 
1; STK11, serine/threonine kinase 11; TSC1, tuberous sclerosis complex subunit 1; TSC2, tuberous sclerosis complex subunit 2.
??????
????
??????????? ???????????????????????????????????? ????????????????????????????? ????????????????????????????????????? ???? ???????????????????????????????????????? ???????????????????????????????????? ?????????????????????????????????????????????????? ???????????????????????????????????????????????????????????? ?????????????????????????????????????????????
?????
????????
????????????????????????????????? ????????????????????????????????????????????????????????????? ???????? ????????????????????????????????????????????????????????
A
B
PI3K Genomic Alteration in Solid Tumors/Millis et al
1191Cancer  April 1, 2019 
(OR, 2.67; P = .024), anal cancers (OR, 1.98; P = .03), 
and nonsquamous head and neck cancers (OR, 2.03; 
P = .019) (Fig. 3A, Table 1). In contrast, for liver 
cholangiocarcinomas, endometrial endometrioid tumors, 
lung and unknown primary squamous cell  carcinomas, 
lobular breast carcinomas, and glioblastomas, alterations 
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in the PI3K or MAPK pathway most likely occurred as 
isolated events.
When all tumors were analyzed, there were no sig-
nificant co-occurrences between PI3K and TP53 pathway 
alterations (Fig. 3B, Table 2). Nonetheless, among other 
tumor types, positive co-occurrences were detected for 
some gastrointestinal tumors, including colorectal can-
cer (OR, 1.55; P < .001), hepatocellular carcinoma (OR, 
2.32; P < .001), and gastric cancer (OR, 2.87; P = .006).
A significant co-occurrence ratio was present 
between PI3K pathway alterations and hormone re-
ceptor alterations in ESR1 and AR (OR, 1.53; P < .01) 
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(Fig. 3C, Table 3). However, this positive correlation was 
restricted to a few tumor types (bladder, colorectal, cor-
pus uteri, prostate, and unknown primary cancers).
Types of Genetic Alterations
Different types of alterations were identified in the 18 
PI3K pathway genes (Supporting Table 2). Only alterations 
that were considered pathogenic or likely pathogenic 
were  reported. Single nucleotide changes were the pre-
dominant genetic alterations in 15 of the18 genes (83%), 
whereas copy number changes were predominant in 
AKT2 (1.6%), AKT3 (0.9%), and PIK3 catalytic subu-
nit 2β (PIK3C2B) (1.2%). Although copy number 
changes and rearrangements were identified infrequently 
??????
????????
????????????????????????????????????????????????????????????????????????????????????????????????????
??????????
??????
??????????? ????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
G
H
Figure 2. Continued
Original Article
1194 Cancer  April 1, 2019 
(11% and 0.9%, respectively), they still represent approxi-
mately 7300 patients for whom these alterations might 
inform potential treatments. Of the single nucleotide 
changes reported, 63% were missense, 29% were non-
sense, and 8% were splice variants (Supporting Fig. 1).
DISCUSSION
PI3K pathway alterations are observed frequently in 
 diverse solid tumors, making this pathway an attractive 
target for cancer therapies. Historically, monotherapy 
against this pathway has had mixed efficacy. An analysis 
of specific alterations in the key genes of the pathway 
and of the co-occurrence of complementary, activated 
resistance signals may inform nuanced treatment  options 
and combination strategies that were not previously con-
sidered. To our knowledge, this is the largest analysis 
to date in terms of both the total number of patients 
evaluated (n = 60,991) and the number of PI3K pathway 
genes interrogated (18 genes), and it includes data for 
multiple, rare cancers that were not previously selected 
by TCGA.
Overall, we report that at least1 PI3K pathway 
alteration occurred in 44% of tumors. For compari-
son, our previous analysis included 19,784 solid tumors 
and reported ≥1 alteration in 38% of patients.5 In that 
previous study, alterations were restricted to PIK3CA, 
PTEN, and AKT1 but also included an analysis of 
PTEN loss by immunohistochemistry (not reported 
here), which was present in 30% of samples. Several 
other studies were cataloged by the cBioPortal,27,28 
including an extensive analysis by TCGA and the 
Memorial Sloan Kettering Impact project.29 This com-
bined analysis included approximately 33,000 patients 
with various types of solid tumors and indicated that 
37% had alterations in ≥1 of the analyzed PI3K path-
way genes.
We also focused on reporting PI3K pathway alter-
ations in rare tumor types, for which few or no studies are 
available.23-26 Overall, PIK3CA continues to be the most 
frequently altered gene, predominantly in squamous cell 
histologies, including anal (32%), vulvar (23%), and un-
known primary (22%) sites. Neuroendocrine carcinomas 
in general were silent for PI3K alterations. Relevant ex-
ceptions occurred, 12% of tumors at colon neuroendo-
crine sites had alterations in FBXW7, and 35% of tumors 
at prostate neuroendocrine sites had PTEN mutations, 
mirroring the general tumor site frequency rather than 
the histology itself.30
Carcinosarcoma was the histologic type with the 
most frequent number of PI3K pathway alterations 
(89%). We included 297 samples (predominantly uterine 
[n = 178] and ovarian [n = 99] in origin), which represent 
the largest series of molecular-profiled carcinosarcomas 
to date. These tumors are rare and usually have a worse 
prognosis compared with carcinomas of the same ana-
tomic site, and scarce therapeutic options are available.31 
The cBioPortal catalog included 78 patients with uterine 
carcinosarcomas and reported PI3K pathway alterations 
in 71% of samples.27 Here, we describe a lower frequency 
of alterations in individual genes compared with previous 
small series that reported mutations in PIK3CA (41%), 
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PTEN (41%), and PIK3R1 (14%).32 A significantly greater 
number of samples and a higher proportion of carcinosar-
comas of ovarian origin in our series may explain these 
differences. It is interesting to note our data suggesting 
that the PI3K landscape of alterations is more similar to 
that of uterine carcinomas than general sarcomas, rein-
forcing the biologic relatedness of both.31 An important 
difference was the greater number of AKT2 alterations in 
carcinosarcomas (12% vs 3% in uterine cancers in gen-
eral vs 2% in solid tumors). AKT2 has been implicated in 
TABLE 1.  Co-Occurrence of Alterations Between the Phosphatidylinositol 3-Kinase Pathway  
and the Mitogen-Activated Kinase Pathwaya
Disease Type
PI3K 
Pathway 
Exclusive 
Alteration
MAPK 
Pathway 
Exclusive 
Alteration
Double 
Mutant
Neither 
Alteration
OR for Altered 
PI3K in MAPK 
Mutant vs Wild 
Type
OR for MAPK 
Mutant in 
PI3K Altered 
vs Wild Type P
All tumors 16,004 17,574 9932 26,450 0.96 0.96 .0001
Anal 107 1 9 93 1.68 7.29 .0252
Biliary 333 924 261 964 0.86 0.90 .0341
Cervix 233 61 56 129 0.74 0.60 .0022
CRC 665 3050 2351 1842 1.64 1.25 .0001
Gastrointestinal NET 169 160 59 666 1.33 1.34 .0343
Gliomas, high grade 1294 115 130 825 0.87 0.75 .0159
Gliomas, low grade 329 171 34 887 0.61 0.58 .0013
Head and neck, nonsquamous 41 15 13 138 2.03 2.46 .0185
Melanoma 160 965 431 444 1.17 1.06 .0485
Mesothelioma 46 13 6 343 2.67 3.16 .0235
NSCLC, adenocarcinoma 1587 3633 2060 3281 1.11 1.07 .0001
NSCLC, squamous 865 191 160 718 0.83 0.74 .0025
Pancreas 61 2170 353 240 0.69 0.95 .0056
Salivary gland 80 72 55 185 1.43 1.45 .0125
SCLC 276 61 44 617 1.36 1.53 .0268
Abbreviations: CRC: colorectal carcinoma; MAPK, mitogen-activated kinase; NET: neuroendocrine tumor; NSCLC: nonsmall cell lung cancer; OR, odds ratio; 
PI3K, phosphatidylinositol 3-kinase; SCLC: small cell lung cancer.
aOnly tumors with a statistically significant association are included in this table.
TABLE 2. Co-Occurrence of Alterations Between the Phosphatidylinositol 3-Kinase Pathway  
and Tumor Protein 53a
Disease Type
PI3K 
Pathway 
Exclusive 
Alteration
TP53 
Alteration
Double 
Mutant
Neither 
Alteration
OR for 
Altered PI3K 
in TP53 
Mutant vs 
Wild Type
OR for 
Mutant TP53 
in PI3K 
Altered vs 
Wild Type P
All tumors 11,227 24,670 14,709 19,354 1.02 1.01 .0835
Adrenal gland 23 72 3 150 0.30 0.33 .0399
Colorectal 1076 4024 1940 868 1.55 1.66 .0001
Corpus uteri 644 329 679 115 0.59 0.78 .0001
Gastrointestinal NET 96 262 132 564 0.98 1.00 .0001
Gliomas, low grade 234 444 129 614 1.82 2.02 .035
HCC 63 131 58 298 2.32 2.50 .0005
HNSCC 176 412 197 234 0.94 0.92 .0007
Kidney 234 116 76 842 0.75 0.83 .0001
Mesothelioma 35 56 17 300 0.91 0.91 .0058
NSCLC, other 253 1121 725 564 0.99 0.99 .0001
NSCLC, squamous 114 751 911 158 1.27 1.11 < .001
Prostate 360 342 385 543 0.43 0.54 .0001
Salivary gland 60 93 75 164 1.33 1.34 .0003
SCLC 21 583 299 95 1.67 1.54 .0005
Skin (nonmelanoma) 37 227 130 134 1.87 1.09 .0007
Soft tissue sarcoma 35 66 20 397 1.10 1.07 .0002
Stomach 206 1201 442 421 2.87 2.55 .0058
Testis 10 13 7 70 0.82 0.92 .0397
Thyroid 72 117 58 437 1.89 1.69 .0001
Unknown primary 673 1730 972 1391 2.34 2.11 .0165
Vagina and vulva 37 38 17 25 1.10 1.07 .0027
Abbreviations: HCC, hepatocellular carcinoma; HNSCC, head and neck squamous cell carcinoma; NET, neuroendocrine tumor; OR, odds ratio; PI3K, phos-
phatidylinositol 3-kinase; SCC, squamous cell carcinoma; SCLC, small cell lung cancer; TP53, tumor protein 53.
aOnly tumors with a statistically significant association are included in this table.
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the epithelial-to-mesenchymal transition,33 for which car-
cinosarcomas represent 1 of the best examples in human 
cancers.
Several reviews have provided a good background 
describing the difficulties in developing efficacious 
PI3K pathway inhibitors as well as the paucity of success-
ful clinical trials that resulted in drug approval targeted 
to specific alterations in this pathway.4,34 Descriptions 
of novel genomic alterations in the pathway that pre-
dict sensitivity to targeted therapies are emerging.35 It 
is important to note that the presence of concomitant 
alterations in alternative pathways may lead to resistance 
to PI3K inhibitors.19,36 Conversely, the presence of PI3K 
alterations can cause resistance to other treatments, es-
pecially hormone therapies.37,38 In the current study, we 
demonstrated that the  co-occurrence of PI3K pathway 
alterations and alterations in the MAPK, TP53, and 
hormone pathways varied according to tumor types, 
as expected. A higher co-occurrence rate of PI3K and 
MAPK alterations was observed in some gastrointestinal 
tumors, including anal and colorectal cancers, which 
could significantly affect the activity of PI3K pathway 
inhibitors.12 ESR1 mutations are being implicated as 
an evolutionary mechanism of acquired resistance to 
endocrine manipulation, especially in patients with 
metastatic, previously treated breast cancer.39 It is also 
noteworthy that, for the first time, we report the ab-
sence of a significant co-occurrence of ESR1 mutations 
with PI3K pathway alterations for breast cancer (OR, 
1.01; P = .85). Nonetheless, a significant correlation 
was detected for uterine cancers, suggesting a distinct 
biologic pathway for the development of resistance 
 between both sites.
AKT1 is 1 of the PI3K pathway genes activated 
by mutations, including the most frequent glutamic 
acid-to-lysine (E17K) hotspot mutation.40 AKT inhib-
itor monotherapy has been tested in this setting with 
initial promising results.41 In this study, we reported 
AKT1 alterations in 1% of samples. Alterations in 
AKT1 are identified more frequently in uterine can-
cers, breast cancers, and undifferentiated carcinomas. 
We also analyzed genetic alterations in STK11, which 
recently has been implicated as a resistance mechanism 
to programmed cell death 1 (PD-1)/PD-1 inhibitors.42 
Although the overall frequency of this alteration was 
5%, it is interesting to note that some tumor types had 
significantly higher frequencies, including NSCLC 
(14%), large cell lung cancer (12%), and cervical cancer 
(12%). These results may be important for the future 
selection of patients for checkpoint inhibitors, espe-
cially in these tumor types.
Our current analysis also highlights the need to use 
a comprehensive genomic profiling approach to identify 
the full spectrum of alteration types that might be iden-
tified in a gene. Hot-spot panels and other sequencing 
methods do not interrogate across all 4 classes of genomic 
alterations (ie, these panels detect single nucleotide vari-
ants but do not identify copy numbers, large insertions 
and deletions, or rearrangements, which occur in an im-
portant minority of patients) (Supporting Table 2). Single 
nucleotide alterations that are not located in common or 
known regions of the genes also would be missed using 
hot-spot technology.
In conclusion, comprehensive genomic profiling of 
solid tumors has revealed frequent genetic alterations in 
several genes of the PI3K pathway. Gynecologic, breast, 
and prostate cancers, along with carcinosarcoma and 
squamous cell carcinomas of different sites, more fre-
quently harbor PI3K alterations. Our data also suggest 
that there are different frequencies of alterations and 
TABLE 3. Co-Occurrence of Alterations Between the Phosphatidylinositol 3-Kinase Pathway and Estrogen 
Receptor 1/Androgen Receptora
Disease Type
PI3K 
Pathway 
Exclusive 
Alteration
ESR1/AR 
Alteration
Double 
Mutant
Neither 
Alteration
OR for 
Altered PI3K 
in ESR1/AR 
Mutant vs 
Wild Type
OR for 
Mutant 
ESR1/AR in 
PI3K Altered 
vs Wild Type P
All tumors 25,025 718 911 43,306 1.53 2.15 .0001
Bladder and urothelial tract 680 0 6 998 2.47 —b .0045
Colorectal 2984 23 32 4869 1.53 2.26 .0031
Corpus uteri 1272 3 51 441 1.27 5.71 .0003
Prostate 523 183 222 702 1.28 1.44 .0001
Unknown primary 1627 16 18 3105 1.54 2.13 .0292
Abbreviations: AR, androgen receptor; ESR1, estrogen receptor 1; OR, odds ratio; PI3K, phosphatidylinositol 3-kinase pathway; SCLC: small cell lung 
cancer.
aOnly tumors with a statistically significant association are included in this table.
bBecause there were no ESR1/AR alterations, a value could not be computed.
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co-occurrence patterns of resistance pathways according 
to tumor types, which can directly affect targeted thera-
peutic opportunities and clinical trial design.
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